About
Jack Scannell is a biotech executive, advisor, and former healthcare analyst best known for coining the term 'Eroom's Law' on declining biopharma R&D productivity. Healthspan Capital describes him as an advisor and CEO of Unify Pharmaceuticals, while a 2023 VitaDAO assessment lists him as CEO of Etheros Pharmaceuticals. Earlier in his career he was Co-Head of European Pharmaceuticals & Biotech at UBS Investment Research, Head of European Healthcare at Sanford Bernstein, led Discovery Biology at E-Therapeutics, and worked at Boston Consulting Group.
Areas of interest
biotechdrug discoverypharmaceutical R&D productivityportfolio modelingpredictive validityneuroscienceneuroprotectionlongevitybiomedical innovationpharma economics